Call +44 (0)1904 798634 or +44 (0)7550 079918

Leading provider of life science market reports and research services


Liquid Biopsy Markets 2019 - 2023 by Cancer Type, Diagnosis, Monitoring & Recurrence Testing with Historical Data including Screening Market Potential with Executive and Consultant Guides

Be the first to review this product

Blood tests replace surgical biopsies. Single screening test for all cancers announced
You can choose to pay by purchase order during checkout

Availability: In stock


* Required Fields

You can choose to pay by purchase order during checkout
Howe Sound Research

Digital downloads direct to your inbox within 24 hours.

First class customer service from our team of experts.

Pay by credit card or request an invoice

Product Description


Updated October 24, 2018 

Table of Contents

This exclusive new report explores the diagnostic, therapy monitoring, recurrence monitoring and screening test opportunities of the global liquid biopsy market.

A revolution in cancer diagnostics is occurring using in vitro blood testing to identify cancer DNA. The technology creates new markets for cancer screening tests. GRAIL, a new company with impressive backing, has announced a single blood test to detect all cancers.  The company is now working on a 10,000-plus subject study called the Circulating Cell-Free Genome Atlas (CCGA) to help identify cancer early. The technology is moving faster than the market. New technology that definitively identifies disease conditions from blood samples is poised to replace expensive invasive surgical biopsy procedures. The market is still in its infancy but has outstanding growth potential, and the impact on the health care industry is enormous. The report forecasts the market size out to 2023; including detailed breakouts for 15 countries and 4 regions along with breakouts for Lung, Breast, Colorectal, Prostate and Other Cancers as well as breakouts by Diagnostic, Therapy Monitoring and Recurrence Monitoring. 

Use independent research that makes you the expert. Get our research team working for you by ordering this comprehensive report. Check all your licensing options but don't worry, your order is available as a credit if you wish to upgrade to more information. Get an extra player on your team as unlimited assistance and breakout data is included with your purchase.

Circulating Tumor Cells? Cell Free DNA? Exosomes? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size.

What is the size of the huge screening opportunity? They are all listed in Chapter 10.

All report data is available in Excel format on request.


Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell is a member of The American Association for Clinical Chemistry. Mr. Powell’s education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Additional Information

Additional Information

Publisher name Howe Sound Research
Format PDF
Page count 292
Publication date 24 Oct 2018
Table of contents

Table of Contents

Sample data tables

Report sample


Write Your Own Review

Only registered users can write reviews. Please, log in or register

Product Tags

Product Tags

Use spaces to separate tags. Use single quotes (') for phrases.